CANCER:

Myelodysplastic Syndrome

SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	CA-4948 Sensitive: C2 – Inclusion Criteria Curis Press Release - 2 weeks	CA-4948 Sensitive: C2 – Inclusion Criteria Curis Press Release - 2 weeks
U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	CA-4948 Sensitive: C2 – Inclusion Criteria Curis Press Release - 2 weeks	CA-4948 Sensitive: C2 – Inclusion Criteria Curis Press Release - 2 weeks
SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials Leuk Lymphoma - 2 weeks	lenalidomide Resistant: C3 – Early Trials Leuk Lymphoma - 2 weeks
No biomarker No biomarker	Myelodysplastic Syndrome MDS	No biomarker No biomarker	Myelodysplastic Syndrome MDS	decitabine/cedazuridine Sensitive: A1 - Approval	decitabine/cedazuridine Sensitive: A1 - Approval
No biomarker No biomarker	Myelodysplastic Syndrome MDS	No biomarker No biomarker	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A1 - Approval	luspatercept-aamt Sensitive: A1 - Approval
Chr del(5q) Chr del(5q)	Myelodysplastic Syndrome MDS	Chr del(5q) Chr del(5q)	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A1 - Approval	lenalidomide Sensitive: A1 - Approval
No biomarker No biomarker	Myelodysplastic Syndrome MDS	No biomarker No biomarker	Myelodysplastic Syndrome MDS	azacitidine Sensitive: A1 - Approval	azacitidine Sensitive: A1 - Approval
No biomarker No biomarker	Myelodysplastic Syndrome MDS	No biomarker No biomarker	Myelodysplastic Syndrome MDS	decitabine Sensitive: A1 - Approval	decitabine Sensitive: A1 - Approval
PDGFRA rearrangement PDGFRA rearrangement	Myelodysplastic Syndrome MDS	PDGFRA rearrangement PDGFRA rearrangement	Myelodysplastic Syndrome MDS	imatinib Sensitive: A1 - Approval	imatinib Sensitive: A1 - Approval
CALR mutation CALR mutation	Myelodysplastic Syndrome MDS	CALR mutation CALR mutation	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline	luspatercept-aamt Sensitive: A2 - Guideline
CALR mutation CALR mutation	Myelodysplastic Syndrome MDS	CALR mutation CALR mutation	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline	lenalidomide Sensitive: A2 - Guideline
MPL W515L MPL W515L	Myelodysplastic Syndrome MDS	MPL W515L MPL W515L	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline	luspatercept-aamt Sensitive: A2 - Guideline
MPL W515L MPL W515L	Myelodysplastic Syndrome MDS	MPL W515L MPL W515L	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline	lenalidomide Sensitive: A2 - Guideline
JAK2 V617F JAK2 V617F	Myelodysplastic Syndrome MDS	JAK2 V617F JAK2 V617F	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline	luspatercept-aamt Sensitive: A2 - Guideline
SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline	luspatercept-aamt Sensitive: A2 - Guideline
JAK2 V617F JAK2 V617F	Myelodysplastic Syndrome MDS	JAK2 V617F JAK2 V617F	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline	lenalidomide Sensitive: A2 - Guideline
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
SETBP1 mutation SETBP1 mutation	Myelodysplastic Syndrome MDS	SETBP1 mutation SETBP1 mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
CBL mutation CBL mutation	Myelodysplastic Syndrome MDS	CBL mutation CBL mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
NRAS mutation NRAS mutation	Myelodysplastic Syndrome MDS	NRAS mutation NRAS mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
SRSF2 mutation SRSF2 mutation	Myelodysplastic Syndrome MDS	SRSF2 mutation SRSF2 mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
ETNK1 mutation ETNK1 mutation	Myelodysplastic Syndrome MDS	ETNK1 mutation ETNK1 mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
STAT3 mutation STAT3 mutation	Myelodysplastic Syndrome MDS	STAT3 mutation STAT3 mutation	Myelodysplastic Syndrome MDS	eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline	eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline
No biomarker No biomarker	Myelodysplastic Syndrome MDS	No biomarker No biomarker	Myelodysplastic Syndrome MDS	eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline	eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	APR-246 Sensitive: B - Late Trials	APR-246 Sensitive: B - Late Trials
No biomarker No biomarker	Myelodysplastic Syndrome MDS	No biomarker No biomarker	Myelodysplastic Syndrome MDS	GS-4721 Sensitive: B - Late Trials	GS-4721 Sensitive: B - Late Trials
DNMT3A mutation + SF3B1 mutation DNMT3A mutation + SF3B1 mutation	Myelodysplastic Syndrome MDS	DNMT3A mutation + SF3B1 mutation DNMT3A mutation + SF3B1 mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: B - Late Trials	lenalidomide Resistant: B - Late Trials
No biomarker No biomarker	Myelodysplastic Syndrome MDS	No biomarker No biomarker	Myelodysplastic Syndrome MDS	MLN4924 Sensitive: B - Late Trials	MLN4924 Sensitive: B - Late Trials
No biomarker No biomarker	Myelodysplastic Syndrome MDS	No biomarker No biomarker	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: B - Late Trials	lenalidomide Sensitive: B - Late Trials
Chr del(5)(q31) Chr del(5)(q31)	Myelodysplastic Syndrome MDS	Chr del(5)(q31) Chr del(5)(q31)	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: B - Late Trials	lenalidomide Sensitive: B - Late Trials
No biomarker No biomarker	Myelodysplastic Syndrome MDS	No biomarker No biomarker	Myelodysplastic Syndrome MDS	Hypomethylating agent + MBG453 Sensitive: B - Late Trials	Hypomethylating agent + MBG453 Sensitive: B - Late Trials
No biomarker No biomarker	Myelodysplastic Syndrome MDS	No biomarker No biomarker	Myelodysplastic Syndrome MDS	venetoclax Sensitive: B - Late Trials	venetoclax Sensitive: B - Late Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	CB-839 Sensitive: C2 – Inclusion Criteria	CB-839 Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	ARO-002 Sensitive: C2 – Inclusion Criteria	ARO-002 Sensitive: C2 – Inclusion Criteria
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	decitabine Sensitive: C2 – Inclusion Criteria	decitabine Sensitive: C2 – Inclusion Criteria
TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C2 – Inclusion Criteria	azacitidine Sensitive: C2 – Inclusion Criteria
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C2 – Inclusion Criteria	venetoclax Sensitive: C2 – Inclusion Criteria
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C2 – Inclusion Criteria	venetoclax Sensitive: C2 – Inclusion Criteria
ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C2 – Inclusion Criteria	venetoclax Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Myelodysplastic Syndrome MDS	IDH2 mutation IDH2 mutation	Myelodysplastic Syndrome MDS	enasidenib Sensitive: C2 – Inclusion Criteria	enasidenib Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	quizartinib Sensitive: C2 – Inclusion Criteria	quizartinib Sensitive: C2 – Inclusion Criteria
CBL mutation CBL mutation	Myelodysplastic Syndrome MDS	CBL mutation CBL mutation	Myelodysplastic Syndrome MDS	quizartinib Sensitive: C2 – Inclusion Criteria	quizartinib Sensitive: C2 – Inclusion Criteria
MECOM mutation + KDM6B mutation MECOM mutation + KDM6B mutation	Myelodysplastic Syndrome MDS	MECOM mutation + KDM6B mutation MECOM mutation + KDM6B mutation	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: C3 – Early Trials	lenalidomide Sensitive: C3 – Early Trials
MECOM mutation + KDM6A mutation MECOM mutation + KDM6A mutation	Myelodysplastic Syndrome MDS	MECOM mutation + KDM6A mutation MECOM mutation + KDM6A mutation	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: C3 – Early Trials	lenalidomide Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
BNIP3L elevation BNIP3L elevation	Myelodysplastic Syndrome MDS	BNIP3L elevation BNIP3L elevation	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials	azacitidine Sensitive: C3 – Early Trials
LDHA elevation LDHA elevation	Myelodysplastic Syndrome MDS	LDHA elevation LDHA elevation	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials	azacitidine Sensitive: C3 – Early Trials
HIF1A overexpression HIF1A overexpression	Myelodysplastic Syndrome MDS	HIF1A overexpression HIF1A overexpression	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials	azacitidine Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials
PIK3CD mutation PIK3CD mutation	Myelodysplastic Syndrome MDS	PIK3CD mutation PIK3CD mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials	lenalidomide Resistant: C3 – Early Trials
PLCG2 mutation PLCG2 mutation	Myelodysplastic Syndrome MDS	PLCG2 mutation PLCG2 mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials	lenalidomide Resistant: C3 – Early Trials
AKT3 mutation AKT3 mutation	Myelodysplastic Syndrome MDS	AKT3 mutation AKT3 mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials	lenalidomide Resistant: C3 – Early Trials
TMB-H TMB-H	Myelodysplastic Syndrome MDS	TMB-H TMB-H	Myelodysplastic Syndrome MDS	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
SF3B1 K700E SF3B1 K700E	Myelodysplastic Syndrome MDS	SF3B1 K700E SF3B1 K700E	Myelodysplastic Syndrome MDS	Hypomethylating agent Sensitive: C3 – Early Trials	Hypomethylating agent Sensitive: C3 – Early Trials
SF3B1 mutation + Chr del(5q) SF3B1 mutation + Chr del(5q)	Myelodysplastic Syndrome MDS	SF3B1 mutation + Chr del(5q) SF3B1 mutation + Chr del(5q)	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials	lenalidomide Resistant: C3 – Early Trials
Chr del(20q) + ASXL1 mutation Chr del(20q) + ASXL1 mutation	Myelodysplastic Syndrome MDS	Chr del(20q) + ASXL1 mutation Chr del(20q) + ASXL1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
Chr del(20q) + ASXL1 deletion Chr del(20q) + ASXL1 deletion	Myelodysplastic Syndrome MDS	Chr del(20q) + ASXL1 deletion Chr del(20q) + ASXL1 deletion	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	decitabine Resistant: C3 – Early Trials	decitabine Resistant: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	decitabine Resistant: C3 – Early Trials	decitabine Resistant: C3 – Early Trials
NPM1 mutation NPM1 mutation	Myelodysplastic Syndrome MDS	NPM1 mutation NPM1 mutation	Myelodysplastic Syndrome MDS	decitabine Sensitive: C3 – Early Trials	decitabine Sensitive: C3 – Early Trials
RRM1 underexpression RRM1 underexpression	Myelodysplastic Syndrome MDS	RRM1 underexpression RRM1 underexpression	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials	azacitidine Sensitive: C3 – Early Trials
Chr del(5q) + TP53 expression Chr del(5q) + TP53 expression	Myelodysplastic Syndrome MDS	Chr del(5q) + TP53 expression Chr del(5q) + TP53 expression	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials	lenalidomide Resistant: C3 – Early Trials
Chr del(5)(q31.1) Chr del(5)(q31.1)	Myelodysplastic Syndrome MDS	Chr del(5)(q31.1) Chr del(5)(q31.1)	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: C3 – Early Trials	lenalidomide Sensitive: C3 – Early Trials
EZH2 mutation EZH2 mutation	Myelodysplastic Syndrome MDS	EZH2 mutation EZH2 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
SLFN11 expression SLFN11 expression	Myelodysplastic Syndrome MDS	SLFN11 expression SLFN11 expression	Myelodysplastic Syndrome MDS	BGB324 Sensitive: C3 – Early Trials	BGB324 Sensitive: C3 – Early Trials
ANG elevation ANG elevation	Myelodysplastic Syndrome MDS	ANG elevation ANG elevation	Myelodysplastic Syndrome MDS	BGB324 Sensitive: C3 – Early Trials	BGB324 Sensitive: C3 – Early Trials
AXL elevation AXL elevation	Myelodysplastic Syndrome MDS	AXL elevation AXL elevation	Myelodysplastic Syndrome MDS	BGB324 Sensitive: C3 – Early Trials	BGB324 Sensitive: C3 – Early Trials
JDP2 overexpression JDP2 overexpression	Myelodysplastic Syndrome MDS	JDP2 overexpression JDP2 overexpression	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials	azacitidine Sensitive: C3 – Early Trials
SPI1 overexpression SPI1 overexpression	Myelodysplastic Syndrome MDS	SPI1 overexpression SPI1 overexpression	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials	azacitidine Sensitive: C3 – Early Trials
Chr del(17p) Chr del(17p)	Myelodysplastic Syndrome MDS	Chr del(17p) Chr del(17p)	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
NPM1 mutation NPM1 mutation	Myelodysplastic Syndrome MDS	NPM1 mutation NPM1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
SETBP1 mutation SETBP1 mutation	Myelodysplastic Syndrome MDS	SETBP1 mutation SETBP1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
IDH1 mutation IDH1 mutation	Myelodysplastic Syndrome MDS	IDH1 mutation IDH1 mutation	Myelodysplastic Syndrome MDS	venetoclax + ivosidenib Sensitive: C3 – Early Trials	venetoclax + ivosidenib Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	MBG453 Sensitive: C3 – Early Trials	MBG453 Sensitive: C3 – Early Trials
ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
ASXL1 deletion ASXL1 deletion	Myelodysplastic Syndrome MDS	ASXL1 deletion ASXL1 deletion	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	azacitidine + MBG453 Sensitive: C3 – Early Trials	azacitidine + MBG453 Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	decitabine + MBG453 Sensitive: C3 – Early Trials	decitabine + MBG453 Sensitive: C3 – Early Trials
ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	venetoclax + azacitidine Sensitive: C3 – Early Trials	venetoclax + azacitidine Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	ALX148 Sensitive: C3 – Early Trials	ALX148 Sensitive: C3 – Early Trials
FGFR1 rearrangement FGFR1 rearrangement	Myelodysplastic Syndrome MDS	FGFR1 rearrangement FGFR1 rearrangement	Myelodysplastic Syndrome MDS	pemigatinib Sensitive: C3 – Early Trials	pemigatinib Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	venetoclax + tagraxofusp Sensitive: C3 – Early Trials	venetoclax + tagraxofusp Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	tagraxofusp Sensitive: C3 – Early Trials	tagraxofusp Sensitive: C3 – Early Trials
WT1 overexpression WT1 overexpression	Myelodysplastic Syndrome MDS	WT1 overexpression WT1 overexpression	Myelodysplastic Syndrome MDS	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials
ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials

Myelodysplastic Syndrome

Associations(102)

Associations
(102)